US5049547A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Composition for stimulating integumental melanocytes
Assignee: University Patents Inc
•
Filing: 1989-04-19
•
Granted: 1991-09-17
•
Expires: 2009-04-19
Abstract
Abstract A pharmaceutically active composition comprising a pharmaceutically acceptable carrier and one or more alpha-MSH or analogues thereof for use in the stimulation of integumental melanocytes in vertebrates in order to bring about the production of melanin is disclosed.
Inventors
- 👤 Victor J. Hruby
- 👤 Mac E. Hadley
- 👤 Robert Dorr
- 👤 Norman Levine
- 👤 Elizabeth Sugg
- 👤 Wayne L. Cody
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 21:14
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/33; A61K38/34; A61K8/00; A61K8/18; A61K8/30; A61K8/64; A61Q; A61Q19/00; A61Q19/04
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
54 words
A pharmaceutical composition for the administration of an active component to stimulate melanin production in a vertebrate which comprises at least one active component of the group: (1) alpha-MSH having the formula Ac--Ser--Tyr--Ser--Met--Glu--His--Phe--Arg--Trp--Gly--Lys--Pro--Val--NH.sub.2 ; (2) alpha-MSH analogues having the formula Ac--Ser--Tyr--Ser--M--Glu--His--D--Phe--Arg--Trp--Gly--Lys--Pro--Val--NH.sub.2 wherein M is selected from the group consisting of Met, Nle, and Cys;
Claim 2
Dependent Claim
54 words
A pharmaceutical composition for the administration of an active component to stimulate melanin production in a vertebrate which comprises at least one active component of the group: (1) alpha-MSH having the formula Ac--Ser--Tyr--Ser--Met--Glu--His--Phe--Arg--Trp--Gly--Lys--Pro--Val--NH.sub.2 ; (2) alpha-MSH analogues having the formula Ac--Ser--Tyr--Ser--M--Glu--His--D--Phe--Arg--Trp--Gly--Lys--Pro--Val--NH.sub.2 wherein M is selected from the group consisting of Met, Nle, and Cys;
Claim 3
Dependent Claim
187 words
(3) analogues of alpha-MSH having the formula R.sub.1 --W--X--Y--Z--R.sub.2 wherein R 1 is selected from the group consisting of Ac-Gly, Ac-Met-Glu, Ac-Nle-Glu, and Ac-Tyr-Glu; wherein W is selected from the group consisting of His and D-His; wherein X is selected from the group consisting of Phe, D-Phe, Tyr, D-Tyr, and (pNO 2 )D-Phe; wherein Y is selected from the group consisting of Arg and D-Arg; wherein Z is selected from the group consisting of Trp and D-Trp; and wherein R 2 is selected from the group consisting of NH 2 , Gly-N 2 and Gly-Lys-NH 2 ; and (4) alpha-MSH analogues selected from the group consisting of [Nle 4 , D-Phe 7 ]-alpha-MSH [Nle 4 , D-Phe 7 ]-alpha-MSH 4-10 [Nle 4 , D-Phe 7 ]-alpha-MSH 4-11 [Nle 4 , D-Phe 7 , D-Trp 9 ]-alpha-MSH 4-11 [Nle 4 , D-Phe 7 ]-alpha-MSH 4-9 said component being present in an amount sufficient to cause the production of melanin in said vertebrate, said composition further comprising a pharmaceutically acceptable carrier for administration of the active component to the vertebrate in which the stimulation of melanin production is desired.
Claim 4
Dependent Claim
187 words
(3) analogues of alpha-MSH having the formula R.sub.1 --W--X--Y--Z--R.sub.2 wherein R 1 is selected from the group consisting of Ac-Gly, Ac-Met-Glu, Ac-Nle-Glu, and Ac-Tyr-Glu; wherein W is selected from the group consisting of His and D-His; wherein X is selected from the group consisting of Phe, D-Phe, Tyr, D-Tyr, and (pNO 2 )D-Phe; wherein Y is selected from the group consisting of Arg and D-Arg; wherein Z is selected from the group consisting of Trp and D-Trp; and wherein R 2 is selected from the group consisting of NH 2 , Gly-N 2 and Gly-Lys-NH 2 ; and (4) alpha-MSH analogues selected from the group consisting of [Nle 4 , D-Phe 7 ]-alpha-MSH [Nle 4 , D-Phe 7 ]-alpha-MSH 4-10 [Nle 4 , D-Phe 7 ]-alpha-MSH 4-11 [Nle 4 , D-Phe 7 , D-Trp 9 ]-alpha-MSH 4-11 [Nle 4 , D-Phe 7 ]-alpha-MSH 4-9 said component being present in an amount sufficient to cause the production of melanin in said vertebrate, said composition further comprising a pharmaceutically acceptable carrier for administration of the active component to the vertebrate in which the stimulation of melanin production is desired.
Claim 5
Dependent Claim
17 words
The composition of claim 1 wherein the component is [Nle 4 , D-Phe 7 ]-alpha-MSH 4-10 .
Claim 6
Dependent Claim
17 words
The composition of claim 1 wherein the component is [Nle 4 , D-Phe 7 ]-alpha-MSH 4-11 .
Claim 7
Dependent Claim
23 words
The composition of claim 1 wherein the component is [Nle 4 , D-Phe 7 , D-Trp 7 , D-Trp 9 ]-alpha-MSH 4-11 .
Claim 8
Dependent Claim
17 words
The composition of claim 1 wherein the component is [Nle 4 , D-Phe 7 ]-alpha-MSH 4-9 .
Claim 9
Dependent Claim
12 words
The composition of claim 1 wherein the component is Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH 2 .
Claim 10
Dependent Claim
12 words
The composition of claim 1 wherein the component is Ac-Ser-Tyr-Ser-Cys-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH 2 .
Claim 11
Dependent Claim
18 words
The composition of claim 1 wherein the component is an analogue of alpha-MSH in which X is D-Phe.
Claim 12
Dependent Claim
19 words
The composition of claim 1 wherein the component is an analogue of alpha-MSH in which R 1 is Ac-Nle-Glu.
Claim 13
Dependent Claim
23 words
The composition of claim 1 wherein the component is an analogue of alpha-MSH in which R 1 is Ac-Nle-Glu, and X is D-Phe.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-09-16 | 1995-03-18 | 1995-09-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-09-16 | 1999-03-18 | 1999-09-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-09-16 | 2003-03-18 | 2003-09-17 | $7700.00 | Window Closed / Lapsed |